TWST - Twist Bioscience, Inc. Company Cash Volume

Corporate emblem and logo of Twist Bioscience, Inc. (TWST)

Steady demand for DNA synthesis provides Twist Bioscience (TWST) with regular revenue, as evidenced by the volume of operating cash flow. However, fierce competition for contracts with tech giants and the risk of dumping create pressure. Effective management is confidently steering the business toward profitability, while 0.58 captures the current state of the liquidity parameter. The cash dynamics on this chart allow for an assessment of the balance between financial security and profitability.

TWST - Twist Bioscience Corp Company Cash Reserve over the range 07/04/2022 - 11/21/2026

Metric breakdowns and analytics for Twist Bioscience Inc (TWST)

- stock value and consensus price forecast:
Basic company analysis:Twist Bio TWST
Product sample of Twist Bioscience, Inc.

This indicator measures the absolute volume of liquid assets, determining the issuer's ability to service obligations and prevent business degradation. By analyzing the cash trajectory, an investor can see how effectively the sales growth of the Twist Bioscience (TWST) Express line covers capital expenditures for laboratory expansion, which is critical for ensuring long-term financial stability and the scaling of DNA platforms.

Key competitors

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Volume TXG|Company Liquid Assets Intellia|Stoke - Company Cash on Hand|BLFS: Company Cash and Cash Equivalents|Wave Life Sciences Corp - Company Cash Volume|Maze Therapeutics, Inc. (MAZE) - Company Cash on Hand|Sionna Therapeutics Inc (SION) - Company Cash Funds|Company Cash on Hand Prime Medicine Corp|Company Cash Funds tayshagtx.com|QURE - Company Cash Position|Company Cash on Hand MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Company Cash Position|Company Cash Volume SLDB (Solid Biosciences Inc.)|Company Cash Balance OCGN|PacBio Corp - Company Cash Volume|Benitec Biopharma Inc. (BNTC) - Company Cash on Hand|DSGN: Company Cash Volume|Company Cash and Cash Equivalents RCKT|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume